Trends in the administration of COVID-19 vaccines with other vaccines in the United States reported to V-safe during December 14, 2020-May 19, 2023.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Austin, Tex. : Landes Bioscience
    • Subject Terms:
      COVID-19 Vaccines*/administration & dosage ; COVID-19 Vaccines*/immunology ; COVID-19*/prevention & control ; COVID-19*/epidemiology; Humans ; United States ; Adolescent ; Adult ; Young Adult ; Child ; Middle Aged ; Aged ; Male ; Female ; Child, Preschool ; Infant ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/immunology ; Vaccination/methods ; Vaccination/trends ; Vaccination/statistics & numerical data ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Aged, 80 and over ; SARS-CoV-2/immunology
    • Abstract:
      Introduction COVID-19 vaccines may be administered with other vaccines during the same healthcare visit. COVID-19 monovalent (Fall 2021) and bivalent (Fall 2022) vaccine recommendations coincided with annual seasonal influenza vaccination. Data describing the frequency of the co-administration of COVID-19 vaccines with other vaccines are limited. Methods We used V-safe, a voluntary smartphone-based U.S. safety surveillance system established by the CDC, to describe trends in the administration of COVID-19 vaccines with other vaccines reported to V-safe during December 14, 2020 - May 19, 2023. Results Of the 21 million COVID-19 vaccinations reported to V-safe, 2.2% (459,817) were administered with at least 1 other vaccine. Co-administration most frequently occurred during the first week of October 2023 (27,092; 44.1%). Most reports of co-administration included influenza vaccine (393,003; 85.5%). Co-administration was most frequently reported for registrants aged 6 months-6 years (4,872; 4.4%). Conclusion Reports of co-administration to V-safe peaked during October 2023, when influenza vaccination most often occurs, possibly reflecting increased opportunities for multiple vaccinations and greater acceptability of the co-administration of COVID-19 vaccine with other vaccines, especially influenza vaccine.
    • References:
      Hum Vaccin Immunother. 2023 Dec 31;19(1):2195786. (PMID: 37039318)
      JAMA Netw Open. 2022 Jul 1;5(7):e2222241. (PMID: 35838667)
      MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. (PMID: 33332292)
      MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. (PMID: 37471262)
      MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552. (PMID: 34735422)
      Vaccine. 2023 Mar 10;41(11):1859-1863. (PMID: 36669964)
      MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441. (PMID: 36355612)
      Vaccine. 2023 Feb 10;41(7):1310-1318. (PMID: 36697313)
      Vaccine. 2023 Jul 19;41(32):4658-4665. (PMID: 37344264)
      Hum Vaccin Immunother. 2022 Nov 30;18(6):2131166. (PMID: 36256633)
      Vaccine. 2023 Sep 7;41(39):5678-5682. (PMID: 37599140)
    • Contributed Indexing:
      Keywords: COVID-19 vaccine; V-safe; co-administration; influenza vaccine
    • Accession Number:
      0 (COVID-19 Vaccines)
      0 (Influenza Vaccines)
    • Publication Date:
      Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240612
    • Publication Date:
      20240612
    • Accession Number:
      PMC11164217
    • Accession Number:
      10.1080/21645515.2024.2361946
    • Accession Number:
      38845409